


## PHARMACEUTICAL 2018



## Paratek Pharmaceuticals Inc. Rank 198 of 349





## PHARMACEUTICAL 2018



## Paratek Pharmaceuticals Inc. Rank 198 of 349

The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -221%, being 56% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	160,486
Cost of Goods Sold	0
Intangible Assets	971
Liabilities, Current	16,789
Liabilities, Non-Current	64,360
Other Assets	530
Other Compr. Net Income	-142
Other Expenses	5,991
Other Liabilities	71
Other Net Income	1,343
Property and Equipment	1,711
Research and Development	60,072
Revenues	12,616
Selling, General and Administrative Expense	36,965

Output Variable	Value in 1000 USD
Assets	163,698
Liabilities	81,220
Expenses	103,028
Stockholders Equity	82,478
Net Income	-89,069
Comprehensive Net Income	-89,140
Economic Capital Ratio	-221%